New frontiers are emerging, which may shape future management strategies like the Fibroblast Growth Factor Receptor 1 Inhibition, which has demonstrated enhanced cytoreductive action in lacrimal gland ACC cell lines [18]. This evidence concerns the gene FGFR1 and adrenal cortex carcinoma.